Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
WNW
News for the people
Downtown
Magazine PRO
22.6
C
London
Sunday, June 15, 2025
Home
Refund Policy
Privacy Policy
Terms & Conditions
Submit Your Press Releases (Free)
Sponsored Posts
About
Facebook
Instagram
Twitter
Youtube
WNW
News for the people
Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
Subscribe
WNW
News for the people
Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
Subscribe
Home
Tags
SinoMab
Tag: SinoMab
Japan – SinoMab BioScience Limited Breakthrough Phase 1b POC Results for...
Editor
-
April 10, 2025
0
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published...
April 17, 2024
0
SinoMab Announces that IND Application of SM17 for the Treatment of...
Editor
-
August 15, 2023
0
SinoMab Submits another IND Application for SM17 for the Treatment of...
Editor
-
June 13, 2023
0
SinoMab Announces IND Application of SM17 for the Treatment of Asthma...
May 22, 2023
0
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China)...
November 5, 2022
0
SinoMab Received the Highest Subsidy from HKSTP
July 9, 2022
0
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of...
June 17, 2022
0
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
June 9, 2022
0
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
February 8, 2022
0
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial...
November 30, 2021
0
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development...
September 17, 2021
0
Get $10 by answering a Simple Survey.
Click Here